ARIVIS AG

Their core work

arivis AG is a German software company specializing in scientific image analysis and 3D/4D visualization tools for life sciences and biomedical research. In H2020 projects, they contributed their imaging and data analysis platform to research consortia studying cellular biology, cancer diagnostics, and blood cell development. Their role is that of a technology provider — supplying the visualization and image processing software that enables researchers to interpret complex microscopy and clinical imaging data.

What they specialise in

How they've shifted over time

All three of arivis AG's H2020 projects started within a narrow window (2015–2016), so there is limited basis for tracking a clear evolution. Their early work combined fundamental biology imaging (red blood cell research, PI3K signaling) with applied clinical imaging (breast cancer decision support). With no projects starting after 2016, it is unclear whether they continued EU-funded research or shifted focus entirely to commercial product development.

arivis AG appears to have used H2020 as a product validation channel (2015–2019) and may have since moved to a purely commercial model — potential partners should verify current research engagement directly.

How they like to work

arivis AG has exclusively participated as a partner, never coordinating a project. They joined medium-to-large consortia (36 unique partners across 10 countries in just 3 projects), suggesting they are brought in as a specialist technology provider rather than driving research agendas. This is a typical pattern for software SMEs — they contribute a specific tool or platform and benefit from real-world validation use cases.

Despite only three projects, arivis AG built connections with 36 distinct partners across 10 countries, reflecting participation in well-populated international consortia. Their network is broadly European with no obvious geographic concentration beyond their German home base.

What sets them apart

arivis AG occupies a niche as a commercial imaging software provider that has been validated through EU-funded biomedical research. Unlike academic imaging groups, they offer a productized platform ready for integration into research workflows. For consortia needing robust 3D/4D image analysis without building tools from scratch, they bring an off-the-shelf solution with demonstrated use in both fundamental biology and clinical decision support contexts.

Highlights from their portfolio

• DESIREE
  Their largest funded contribution (EUR 350,250), applying image analysis to a clinical breast cancer decision support system — the clearest bridge from their technology to patient-facing healthcare.
• RELEVANCE
  A Marie Skłodowska-Curie training network on red blood cell biology, where arivis provided cellular imaging capabilities for studying erythrocyte life cycles and stem cell differentiation.